VBIV Stock Price: VBI Vaccines Inc surges as analyst says firm “could have the best coronavirus vaccine”

  • NASDAQ: VBIV is set to surge to the highest levels in a month.
  • Enthusiasm over VBI Vaccines Inc's potent pan-coronavirus immunization candidate is driving shares higher.
  • In a highly competitive race for COVID-19 vaccines, quality may mark a difference.

Vaccinating against more than one coronavirus – and doing it better than competitors – is what VBI Vaccines is seeking. The Massachusets-based pharma firm has performed several preclinical trials on mice and claims that they have provoked a substantial creation of antibodies and other mechanisms to defend against coronaviruses. 

The use of the plural is no mistake – one of the candidates is a "trivalent" pan-coronavirus vaccine, protecting against the raging SARS-Cov-2, the 2003-era SARS-CoV, and also MERS-CoV, which dates back to 2015. 

Another advantage is that VBI's vaccine may require only one shot – allowing faster distribution of immunization to the world population. 

Skeptics have noted that optimism in the preclinical stage may not necessarily translate into success with human subjects. Moreover, several large pharma firms are already conducting Phase 3 tests – injecting their solutions to around 30,000 subjects. 

Nevertheless, the AstraZeneca/University of Oxford project – considered the most advanced – may work for only 12-24 months. With dozens of companies working on a solution – and limited production capacity – there is still time for smaller firms to provide potentially better solutions

The high level of antibodies created – at least among mice – may be a differentiating factor. That has led Steven Seedhouse, an analyst with Raymond James, to upgrade the stock to "strong-buy", adding that "VBI may be in an entirely different ballpark for potency vs. any other vaccine we've seen."

VBIV Stock Forecast

NASDAQ: VBIV is quoted at around $4.50 in Friday's pre-market trading, building on top of its whopping 32% leap on Thursday. VBI Vaccines is on course to hit the highest since late July, a one-month high. The 52-week high of $6.83 is the bullish upside target. Support awaits at $3.19, August's low.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Feed news

Latest Forex News

Latest Forex News

Editors’ Picks

EUR/USD stays defensive above 1.1300 as Omicron, inflation concerns loom

EUR/USD is trading below 1.1350, consolidating the biggest daily jump in fortnight. The US dollar pauses its rebound amid cautious optimism. Omicron, US-China woes keep investors on the edge, Rising US inflation expectations underpin the yields. US jobless claims, Omicron updates closely eyed.


GBP/USD trades with modest gains above 1.3200 mark, lacks follow-through

GBP/USD is trading flat above 1.3200, struggling to capitalize on the overnight goodish rebound from a one-year low. Fresh COVID-19 jitters pushed back BoE rate hike expectations and undermined the pound. Resurgent USD demand further stalled aggressive bullish bets.


Gold traders seem non-committed below 200/100-DMA, US CPI awaited Premium

Gold prices inched higher on Wednesday and touched a one-week high, albeit struggled to capitalize on the move and faced rejection near the very important 200-day SMA. Investors seemed reluctant to place aggressive bets ahead of the key US consumer inflation data.

Gold News

Why MATIC price could soon see a meteoric rise toward the round level of $4

MATIC price appears to be ready for a major upswing toward $3.84 as Polygon presented a bullish chart pattern on the daily chart. The governing technical pattern suggests that the layer-2 token is preparing for a 62% climb.

Read more

Cyber Monday 2021 Discounts!

Glued to your trading screen on Cyber Monday? Upgrade your skills by signing up for FXStreet’s Premium service, offered at a discount of up to 50%. Fellow traders have already taken advantage of Black Friday profits. What about you? 

Subscribe now!